Acquired CDMO GenIbet Biopharmaceuticals was acquired by Recipharm in January 2022, indicating access to larger manufacturing networks, capital, and potential integration opportunities for expanded clinical trial material and early-phase production services.

Full Service Offers end-to-end cGMP capabilities from process development to fill and finish, enabling clients to move from bench to clinic in one facility, which is attractive for sponsors seeking simplified vendor management and faster timelines.

Viral and Gene Specializes in viral seed stock production and cell and gene therapy production, presenting cross-sell opportunities with vectors, viral therapies, and microbiome-related projects amid growing gene therapy pipelines.

European Presence Based in Oeiras, Portugal with cGMP manufacturing focus, offering proximity to European sponsors and potential for EU regulatory support, supply chain resilience, and faster clinical material delivery within the region.

Recognition & Growth Municipal merit award and continued service offerings suggest credibility and local reputation, which can be leveraged in outreach to regional biotech clusters, academic partners, and early-stage companies seeking trusted CDMOs.